Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search

Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announces a month-long celebration of the 20th Anniversary of the TECNIS® platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs (intraocular lenses) are built.

Twenty years ago, a team of researchers and innovators created TECNIS®, setting in motion two decades of breakthroughs, including the world’s first aspherical lens and extended depth of focus lens. Today1, not only does TECNIS offer a distinct quality of vision that allows patients to “See More,” it is also the broadest portfolio of IOLs worldwide, providing surgeons with a variety of solutions to treat different visual conditions.

“The innovation of the TECNIS® platform was a revolutionary advancement in IOL design and composition that changed cataract surgery forever by introducing the concept of quality of vision,” said Dr. Eric Donnenfeld, MD, Clinical Professor of Ophthalmology, New York University.”*** “The TECNIS® IOL was the first to employ negative spherical aberration and cancel the positive spherical aberration of the cornea achieving improved visual acuity, contrast sensitivity and reducing chromatic aberration. On behalf of my patients and my practice, congratulations to Johnson & Johnson Vision and TECNIS® on 20 years of improving patient outcomes in cataract surgery.”

“Many ophthalmologists can help restore their patients to 20/20 vision during their cataract procedure by addressing their patient’s vision needs with a presbyopia-correcting IOL, a Toric IOL, or some combination of both. But quality vision is about so much more than the ability to see 20/20,” said Rajesh K. Rajpal****, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision. “It’s about delivering clarity and contrast regardless of lighting or contrast conditions and sustaining that visual performance for the life of the lens. This month, we’re celebrating TECNIS, because of the breakthrough 20 years ago, but also the breakthroughs it continues to enable today.”

In celebration of 20 years, Johnson & Johnson Vision is launching the “See More” campaign to educate patients and physicians on what is possible with cataract surgery and how the TECNIS® portfolio unlocks greater potential for patients. Additionally, Johnson & Johnson Vision is donating $20,000 to the Himalayan Cataract Project (HCP)|Cure Blindness in honor of the organization’s dedication to spread cataract awareness. HCP | Cure Blindness is an independent, nonprofit organization that works to eradicate preventable blindness in countries across the globe and has screened and treated more than 11.5 million people and performed more than 940,000 surgeries in 20 countries.

Johnson & Johnson Vision will continue to roll out the campaign throughout 2021 by launching a global story search. Stories inside the U.S. about how cataract surgery has enabled patients to “See More” via video, photo or text will be collected at https://www.jjvision.com/tecnis-see-more; stories outside of the U.S. will be collected in accordance with the local and regional data privacy regulations. These “See More” patient stories will represent the true reach of the TECNIS® platform.

“For two decades, we’ve dedicated ourselves to creating breakthroughs in cataract treatment and delivering the best optics available in terms of quality of vision. We believe the quality of the lens is only as good as the platform it is built on — that’s why TECNIS® is both our legacy and our future. With the global expansion of our new TECNIS® IOL lenses in 2021, we will be expanding access to the broadest IOL portfolio available on the market,” said Nikki Sidi*****, Vice President, Global Strategic Marketing, Surgical Vision at Johnson & Johnson Vision. “We are excited to celebrate TECNIS® 20th anniversary this year and continue to offer more lenses to more patients than ever before.”

In 2021, Johnson & Johnson Vision will continue to roll out new TECNIS® IOLs across the globe including TECNIS Synergy™ IOL, TECNIS Symfony™ IOL, and TECNIS Eyhance™ IOL, all available at launch with astigmatism correcting options under the next-generation Toric II platform.

Patients who want to learn more about the TECNIS® portfolio can visit https://www.beyondcataracts.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version